Wave Life Sciences Ltd. (WVE) has a negative trailing P/E of -6.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 10.0 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -16.03%, forward earnings yield 9.98%.
Criteria proven by this page:
Overall SharesGrow Score: 61/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -10.8 | -0.06 | 4.42 | 401.51 | - |
| 2017 | -9.1 | -0.16 | 6.66 | 251.25 | - |
| 2018 | -8.3 | -0.26 | 16.60 | 84.50 | - |
| 2019 | -1.4 | -0.30 | 3.79 | 16.99 | - |
| 2020 | -2.1 | 0.07 | 3.41 | 15.38 | - |
| 2021 | -1.3 | 0.03 | 5.01 | 3.97 | - |
| 2022 | -3.4 | 0.26 | -12.24 | 151.27 | - |
| 2023 | -9.3 | 0.13 | 13.52 | 4.73 | - |
| 2024 | -17.6 | -0.60 | 8.16 | 15.79 | - |
| 2025 | -14.0 | -0.19 | 5.45 | 67.10 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-2.43 | $1.49M | $-55.4M | -3730.7% |
| 2017 | $-3.85 | $3.7M | $-102.04M | -2754.7% |
| 2018 | $-5.06 | $14.41M | $-146.65M | -1017.4% |
| 2019 | $-5.30 | $15.98M | $-179.5M | -1123% |
| 2020 | $-3.82 | $20.08M | $-149.91M | -746.7% |
| 2021 | $-2.36 | $40.96M | $-122.25M | -298.4% |
| 2022 | $-2.05 | $3.65M | $-161.82M | -4434.7% |
| 2023 | $-0.54 | $113.31M | $-57.51M | -50.8% |
| 2024 | $-0.70 | $108.3M | $-97.01M | -89.6% |
| 2025 | $-1.21 | $42.73M | $-204.38M | -478.3% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.33 | $-1.73 – $-1.19 | $34.24M | $15.86M – $42.14M | 12 |
| 2027 | $-1.36 | $-1.98 – $-0.25 | $66.74M | $32.39M – $110.96M | 11 |
| 2028 | $-1.20 | $-2.35 – $0.18 | $155.24M | $153.81M – $156.67M | 10 |
| 2029 | $-0.57 | $-0.98 – $-0.19 | $324.45M | $155.46M – $500.32M | 4 |
| 2030 | $0.58 | $0.19 – $0.99 | $689.81M | $330.51M – $1.06B | 4 |
